The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1 ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide ... Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.

Higher body appreciation was highlighted as a protective factor against GLP-1 use. However, it is important to note that the study's cross-sectional design means these findings are correlational ...

Treatment satisfaction significantly improved among GLP-1 users in six studies. Breit said the review shows ... use of GLP-1s with the indication to treat mental illness,” Breit said. “Future ...

Tirzepatide use increased significantly since January ... The GLMs assessed in the study include GLP-1 receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, metformin, insulin ...

The observational, real-life retrospective cohort study found that in adults with obesity and type 2 diabetes but no prior heart disease, glucagon-like peptide-1 receptor agonists (GLP-1RAs ...